Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Biotech buyouts.

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Oct 10, 2022 5:01pm

169 Views

Post# 35016101

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Biotech buyouts.

jimsenior,

IIRC, Matt was the last of the "founders" who had some kind of royalty agreement on sales. All the other founders dropped off (e.g., Brad). Whether that agreement still exists I do not know. If it did, and he were not compensated in a purchase, he could have an incentive to avoid a change of ownership. On the other hand, he may have some kind of change of ownership compensation also. I do not know.

I always thought that an agreement of that nature, plus options, explained the lack of buying of shares on the open market. Of course, if they are at present in negotiations, they would be in a black out period.

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December